Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.